Alendronate disturbs vesicular trafficking in osteoclasts

被引:74
作者
Alakangas, A
Selander, K
Mulari, M
Halleen, J
Lehenkari, P
Mönkkönen, J
Salo, J
Väänänen, K
机构
[1] Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland
[2] Univ Oulu, Dept Surg, SF-90220 Oulu, Finland
[3] Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland
[4] Univ Helsinki, Cent Hosp, Dept Orthopaed & Traumatol, SF-00260 Helsinki, Finland
关键词
alendronate; bone resorption; bisphosphonates; osteoclast; vesicle transport;
D O I
10.1007/s002230010047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The nitrogen-containing bisphosphonate alendronate inhibits osteoclast-mediated bone resorption through inhibition of the mevalonate pathway. This results in impaired protein prenylation and may affect the function of small GTPases in osteoclasts. Since these proteins are important regulators of vesicle transport in cells. we investigated the possible interference of alendronate with these processes in isolated rat osteoclasts. We show here that alendronate-induced inhibition of bone resorption coincides with accumulation of tartrate-resistant acid phosphatase- and electron dense material-containing tubular vesicles in osteoclasts. Alendronate-induced changes in osteoclasts also included widening of the sealing zone areas and incomplete organization of tight attachments and ruffled borders. Osteoclasts also appeared partially detached from the bone surface, and organic matrix was typically dissolved only at the edges of the resorption pits on alendronate-coated bone slices. In contrast, resorption pits on the control and clodronate-coated bone slices were thoroughly resorbed. Inhibition of bone resorption by alendronate was not. however, related to a decrease in osteoclast number. In conclusion, our findings suggest that alendronate inactivates osteoclasts by mechanisms that impair their intracellular vesicle transport, apoptosis being only a secondary phenomenon to this.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 42 条
  • [1] Expression and regulation of RAB3 proteins in osteoclasts and their precursors
    Abu-Amer, Y
    Teitelbaum, SL
    Chappel, JC
    Schlesinger, P
    Ross, FP
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (11) : 1855 - 1860
  • [2] Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry
    Auriola, S
    Frith, J
    Rogers, MJ
    Koivuniemi, A
    Mönkkönen, J
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1997, 704 (1-2): : 187 - 195
  • [3] BARTLETT GR, 1959, J BIOL CHEM, V234, P466
  • [4] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
    Benford, HL
    Frith, JC
    Auriola, S
    Mönkkönen, J
    Rogers, MJ
    [J]. MOLECULAR PHARMACOLOGY, 1999, 56 (01) : 131 - 140
  • [5] Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
    Bergstrom, JD
    Bostedor, RG
    Masarachia, PJ
    Reszka, AA
    Rodan, G
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) : 231 - 241
  • [6] BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
  • [7] BOONEKAMP PM, 1986, BONE MINER, V1, P27
  • [8] ALENDRONATE TREATMENT OF THE POSTMENOPAUSAL OSTEOPOROTIC WOMAN - EFFECT OF MULTIPLE DOSAGES ON BONE MASS AND BONE REMODELING
    CHESTNUT, CH
    MCCLUNG, MR
    ENSRUD, KE
    BELL, NH
    GENANT, HK
    HARRIS, ST
    SINGER, FR
    STOCK, JL
    YOOD, RA
    DELMAS, PD
    KHER, U
    PRYORTILLOTSON, S
    SANTORA, AC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 99 (02) : 144 - 152
  • [9] The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPase
    David, P
    Nguyen, H
    Barbier, A
    Baron, R
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (10) : 1498 - 1507
  • [10] Endo N, 1996, J BONE MINER RES, V11, P535